Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab and Radiotherapy in Early-stage Favorable cHL (CARHL)
NCT04373083Phase 2Withdrawn
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2020
- Primary completion
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
01
Overview
Phase 2, randomised, open-label trial of cemiplimab in classical Hodgkin lymphoma (cHL) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Progression-free survival at 1 year. Planned start Nov 2020; status: withdrawn.
02
Drugs
cemiplimab
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT04373083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04373083.